| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Transplantation Laboratory, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205
The lung is known to be particularly susceptible to complement-mediated injury. Both C5a and the membrane attack complex (MAC), which is formed by the terminal components of complement (C5b-C9), can cause acute pulmonary distress in nontransplanted lungs. We used C6-deficient rats to investigate whether MAC causes injury to lung allografts. PVG.R8 lungs were transplanted orthotopically to MHC class I-incompatible PVG.1U recipients. Allografts from C6-sufficient (C6+) donors to C6+ recipients were rejected with an intense vascular infiltration and diffuse alveolar hemorrhage 7 days after transplantation (n = 5). Ab and complement (C3d) deposition was accompanied by extensive vascular endothelial injury and intravascular release of von Willebrand factor. In contrast, lung allografts from C6-deficient (C6-) donors to C6- recipients survived 13–17 days (n = 5). In the absence of C6, perivascular mononuclear infiltrates of ED1+ macrophages and CD8+ T lymphocytes were present 7 days after transplantation, but vascular endothelial cells were quiescent, with minimal von Willebrand factor release and no evidence of alveolar hemorrhage or edema. Lung allografts were performed from C6- donors to C6+ recipients (n = 5) and from C6+ donors to C6- recipients (n = 5) to separate the effects of systemic and local C6 production. Lungs transplanted from C6+ donors to C6- recipients had increased alveolar macrophages and capillary injury. C6 production by lung allografts was demonstrated at the mRNA and protein levels. These results demonstrate that MAC causes vascular injury in lung allografts and that the location of injury is dependent on the source of C6.
This article has been cited by other articles:
|
|
 |
|
  F. Gueler, S. Rong, W. Gwinner, M. Mengel, V. Brocker, S. Schon, T. F. Greten, H. Hawlisch, T. Polakowski, K. Schnatbaum, et al. Complement 5a Receptor Inhibition Improves Renal Allograft Survival J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2302 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Iwata, A. Philipovskiy, A. J. Fisher, R. G. Presson Jr., M. Chiyo, J. Lee, E. Mickler, G. N. Smith, I. Petrache, D. B. Brand, et al. Anti-Type V Collagen Humoral Immunity in Lung Transplant Primary Graft Dysfunction J. Immunol., October 15, 2008; 181(8): 5738 - 5747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Horne, J. M. Zimmerer, M. G. Fisher, K. E. Lunsford, G. Nadasdy, T. Nadasdy, N. van Rooijen, and G. L. Bumgardner Critical Role of Effector Macrophages in Mediating CD4-Dependent Alloimmune Injury of Transplanted Liver Parenchymal Cells J. Immunol., July 15, 2008; 181(2): 1224 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nozaki, H. Amano, A. Bickerstaff, C. G. Orosz, A. C. Novick, K. Tanabe, and R. L. Fairchild Antibody-Mediated Rejection of Cardiac Allografts in CCR5-Deficient Recipients J. Immunol., October 15, 2007; 179(8): 5238 - 5245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. McDyer Human and Murine Obliterative Bronchiolitis in Transplant Proceedings of the ATS, January 1, 2007; 4(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Tinckam and A. Chandraker Mechanisms and Role of HLA and non-HLA Alloantibodies Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Wilkes, T. M. Egan, and H. Y. Reynolds Lung Transplantation: Opportunities for Research and Clinical Advancement Am. J. Respir. Crit. Care Med., October 15, 2005; 172(8): 944 - 955. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
